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Which albumin should we measure? Albumin circulates in the
blood as a single homogeneous protein. During passage to the
urine it can undergo configuration and digestive change, pro-
ducing moieties not equally detected by the various methods
currently routinely used for quantifying albuminuria. In nor-
mal urine, albumin is not the most common protein. In mi-
croalbuminuric states, detection techniques of great sensitively
and specificity are required, looking for the whole molecule,
immunoreactive moieties, peptide fragments, or all of these.
We are unsure of the most accurate technique in terms of pa-
tient prognosis; accordingly, we must now ask “Which albumin
should we measure?”
The recent interest in albumin in urine as a prognos-
tic indicator in a wide variety of diseases warrants some
reflection on what “albumin” means. Albumin is a very
old word, derived from the Latin albus = white, referring
to egg-white. Albumin is derived from the same root,
although conventionally used to refer to pure proteins.
Hence, albumins are a group of proteins characterized
by heat coagulability and stability in dilute salt solutions
[1].
Albuminuria
Around the turn of the 18th century many wrote of
coagulable urine, including William Wells (1757–1817),
who correctly concluded that the coagulable material was
derived from the blood [2]. Richard Bright linked kidney
disease, dropsy, and albuminuria in 1836 with the paper
“Cases and Observations Illustrative of Renal Diseases
Accompanied with the Secretion of Albuminous Urine”
[2, 3].
The point of this brief historic review, if there is one,
is that the meaning of a word can change, and that the
meaning of albuminuria has changed as the methods to
detect and characterize proteins have evolved. Interest-
ingly, the word proteinuria was introduced later, but the
words albuminuria and proteinuria have often been used
interchangeably—which clearly they are not.
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Plasma albumin
Human albumin is coded in the q11-q22 region of
chromosome 4, and circulates as a carbohydrate-free
polypeptide chain of 585 amino acids, cross linked by 17
disulphide bonds, molecular mass 66,439 [1]. The disul-
phides are positioned in a repeating series of nine loop-
link-loop structures centered around eight sequential
Cys-Cys pairs. X-ray crystallography shows the molecule
has a basic shape, somewhat romantically described as
“heart shaped” [4]. However, the molecule can change
form rapidly. This flexibility has been attributed to its
loop-link-loop structure. Hence, albumin, as with many
other proteins in solution, is not in a “platonic” state, but
is a “kicking and screaming stochastic molecule” [1].
Genetic variants of albumin are very rare. Bisalbu-
minemia with heterozygosity of normal and variant alle-
les is the most common, and analbuminemia, a complete
lack of circulating albumin, is extraordinarily rare and
associated with mild edema, hyperlipidemia, and suscep-
tibility to carcinogens and other toxins [1].
Albumin is characterized by its ability to bind to a wide
variety of molecules, with “scavenger-like traits” making
it a “haven for wanted and unwanted ligands” [1]. Rel-
evant to vascular disease, fatty acid binding by albumin
is an important factor in maintaining blood lipid levels.
Some prostanoids (PG-D2 and PG-E2) are inactivated,
while others (leukotriene A4 and thromboxane A2) are
stabilized by binding to albumin [1]. Scavenging of re-
active oxygen species (ROS) is another vasculoprotec-
tive role of albumin [5]. Other ligands include bilirubin,
calcium, hormones, and a variety of drugs, including as-
pirin and warfarin. Prolonged uremia significantly alters
the ligand-binding properties of albumin, and albumin
contributes to whole blood acid-base buffering capacity.
Constituting 60% of total plasma protein, and with low
molecular weight, albumin contributes about 80% of the
colloid osmotic pressure.
In tissue culture, albumin is a requisite environmen-
tal molecule, perhaps because of ROS scavenging [5].
In capillaries, albumin with other factors, especially oro-
somucoid, has been demonstrated to be necessary for
maintenance of glomerular permselectivity [6], though
this seems not to be the case in Nagase analbuminemic
rats [7].
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Renal handling of albumin
Though there is still controversy regarding the mech-
anism [4, 8], a variety of studies in normal rats and man
indicate that some albumin does pass through the
glomerular filtration barrier; conservatively 0.1 to 0.6
mg/dL or 150 to 800 mg/day in man (reviewed in [9]), al-
though others have suggested the amount may be much
greater [4]. Whether filtered albumin differs qualitatively
from nonfiltered is unknown. The majority of this al-
bumin is resorbed by proximal tubular cells, where re-
ceptors, particularly megalin and cubulin, deliver the
albumin to the vacuolar lysosomal system, where an in-
jurious cascade can be initiated [10, 11].
This process was once believed to result in total break-
down to amino acids, which were then delivered to the
circulation. However, recently it has been shown that
when tritium-labeled albumin is injected into humans,
the majority of tritium-labeled peptides in the urine are
low molecular weight (<10,000 daltons). It has been pro-
posed that these fragments represent lysosomal products
regurgitated to the tubular lumen [4].
Albumin in the urine
Small amounts of intact albumin are present in the
urine of normal individuals (probably with the exception
of genetic analbuminemics). Increased amounts of uri-
nary intact albumin or its fragments can be a result of in-
creased glomerular filtration, altered tubular resorption,
or both. Albuminuria is a continuous variable, ranging
from very little in the normal individual, to the massive
amounts found in the nephrotic syndrome.
Consequent upon the structural flexibility and the lig-
and binding, circulating albumin exhibits chemical and
physical microheterogeneity. It should be no surprise that
by the time the albumin gets to the urine, even greater
heterogeneity exists. The presence of albumin peptide
fragments has been mentioned as one aspect of the het-
erogeneity of albumin-derived urinary products.
To complicate matters further it has recently been
shown that all intact albumin molecules in the urine are
not identified by immunoassays using antialbumin an-
tibodies [4]. Using high-performance liquid chromatog-
raphy (HPLC) to identify intact albumin molecules in
diabetic urine, it has been demonstrated that the amount
of albumin detected by HPLC exceeds that identifiable by
radioimmunoassay. Some albumin molecules may have
undergone steric modification or ligand binding such that
the immunoreactive sites have become obscured.
When there is a large amount of albumin in the urine,
this is of little practical concern because it will be de-
tected by fairly nonspecific methods, such as precipita-
tion or dye binding, as well as the highly specific im-
munoassays. In microalbuminuric states, however, there
are small quantities of albumin and equivalent amounts
of other proteins, such as Tamm Horsfall uromodulin.
Here, the sensitivity and specificity of the assay and the
molecule to be detected may become critical. Studies to
date have shown the value of dipsticks, precipitation, and
immunoassays to detect microalbuminuria. If microalbu-
minuria reflects changes occurring at the filtration mem-
brane level, the evaluation of albumin in all three states
(whole molecules, antibody-recognizable molecules, and
peptide fragments) may be required. Whether these are
of relevance to renal or vascular disease progression re-
quires clarification.
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